RICHARD /CA/ MURRAY - 09 Jan 2023 Form 4 Insider Report for Jounce Therapeutics, Inc.

Role
CEO and President, Director
Signature
/s/ Caroline Gammill, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
09 Jan 2023
Net transactions value
-$50,075
Form type
4
Filing time
11 Jan 2023, 19:32:15 UTC
Previous filing
03 Feb 2022
Next filing
06 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Sale $22,210 -20,191 -7.4% $1.10 252,886 09 Jan 2023 Direct F1, F2
transaction JNCE Common Stock Sale $27,864 -24,879 -9.8% $1.12 228,007 10 Jan 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
F2 Represents the weighted average share price of an aggregate total of 20,191 shares sold in the price range of $1.03 to $1.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 24,879 shares sold in the price range of $1.05 to $1.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Exhibit 24 - Power of Attorney